1. Quality Control Indicators for Transurethral Resection of Non–Muscle-Invasive Bladder Cancer
   Murat Akand et al, 2019, Clinical Genitourinary Cancer CrossRef
2. Comparative study between mitomycin C versus Bacillus Calmette-Guérin (BCG) in high-risk non-muscle-invasive bladder cancer
   Mohamed Mahmoud Abdelfatah Zaza et al, 2024, Urologia Journal CrossRef
3. Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmette‐Guérin (BCG) treatment
   Pertti Nurminen et al, 2019, BJU International CrossRef
4. Non–muscle‐invasive bladder cancer: Intravesical treatments beyond Bacille Calmette‐Guérin
   Vignesh T. Packiam et al, 2017, Cancer CrossRef
5. Benzyl isothiocyanate suppresses IGF1R, FGFR3 and mTOR expression by upregulation of miR-99a-5p in human bladder cancer cells
   Ji-Fan Lin et al, 2019, International Journal of Oncology CrossRef
6. Recurrent Sigmoid Diverticulitis After Intravesical Bacillus Calmette-Guérin (BCG) Immunotherapy for Bladder Cancer
   Ayesha Kamal et al, 2021, SN Comprehensive Clinical Medicine CrossRef
7. Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway
   Kehua Jiang et al, 2017, Oncology Letters CrossRef
8. A pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine)-decorated liposome system for protein delivery: An application for bladder cancer treatment
   Marian Vila-Caballer et al, 2016, Journal of Controlled Release CrossRef
9. Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model
   Zongren Wang et al, 2018, BMC Cancer CrossRef